Apellis Completes a $403 Million Follow-On Offering

Healthcare

Apellis follow-on offering


Summary

Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 10,062,500 shares of its common stock at a public offering price of $40.00 per share, for total gross proceeds of $402.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. The offering included the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares of common stock.

Baird served as lead manager on this offering.

About

Apellis is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. A leader in targeted C3 therapies, Apellis aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology and neurology. Apellis Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
CONTACT US TO LEARN MORE
Healthcare

Apellis follow-on offering

Date
November 2021
Company
Apellis Pharmaceuticals, Inc.
Transaction
Equity Capital Markets
Sectors
Healthcare
Verticals
Biotechnology & Pharmaceuticals
Target Geography
North America

Share